CV Sciences, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joseph D. Dowling
- Full Time Employees
- 47
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 9530 Padgett Street San Diego CA United States of America 92121
- IPO Date
- Feb 12, 2013
- CIK
- 0001510964
- Website
- cvsciences.com
- Similar Companies
- Business
- CV Sciences, Inc. is a consumer wellness company specializing in the development, manufacture, marketing, and sale of nutraceuticals and plant-based food products, with a primary focus on hemp extracts and science-backed natural ingredients. Its core products include the PlusCBD™ branded hemp extract supplements available in various forms such as tinctures, softgels, gummies, and topicals, as well as the +PlusHLTH™ cannabinoid-free supplement line, +PlusCBD™ Extra Support Sleep and Calm Gummies, +PlusCBD™ Reserve gummies, and a range of pet health products. The company also offers the Aura Collection, which features THC-infused products including fast-acting Fizz Tablets, Serene and Illuminate Gummies, designed to promote relaxation and well-being. CV Sciences operates primarily in North America and sells through multiple channels including B2B and B2C retail outlets. Founded in 2014, the company is headquartered in San Diego, California. Recent significant developments at CV Sciences include the acquisition of Elevated Softgels, a profitable manufacturer of softgels and tinctures, allowing the company to in-source select PlusCBD™ product manufacturing to achieve cost efficiencies and expand production capabilities. In late 2024, CV Sciences entered a definitive agreement to acquire Extract Labs, a GMP-certified and FDA-registered manufacturer and distributor of premium cannabinoid products such as gummies, topicals, and tinctures, which is expected to expand CV Sciences’ product range and accelerate new product development. The company has strategically diversified its portfolio by launching new product lines such as Ignite, a men's performance formula, and Lunar Fox, a plant-based food line, as well as expanding its cannabinoid and non-cannabinoid wellness offerings. In 2025, CV Sciences reported improved gross margins, positive adjusted EBITDA, and increased cash balances, reflecting progress toward profitability and efficient cost management. CV Sciences serves the wellness and natural products market, targeting consumers seeking hemp-based supplements, cannabinoid and non-cannabinoid health products, and pet wellness solutions. Its strategic focus includes organic growth through innovation, expansion of manufacturing capabilities, and acquisitions aimed at broadening its product portfolio and distribution footprint. The company remains the top-selling hemp extract brand in natural product retail in the U.S., according to industry data provider SPINS, and continues to leverage its brand and operational synergies to drive long-term shareholder value.
CV Sciences Expands +PlusHLTH(TM) Portfolio with Personalized Wellness Solutions for Healthy Aging
CV Sciences, Inc. (CVSI) Shareholder/Analyst Call Prepared Remarks Transcript
CV Sciences, Inc. (CVSI) Q1 2026 Earnings Call Prepared Remarks Transcript
CV Sciences, Inc. To Announce First Quarter 2026 Results On May 14, 2026
CV Sciences, Inc. (CVSI) Q4 2025 Earnings Call Prepared Remarks Transcript
CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results
CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026
CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth
CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness
CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD
CV Sciences, Inc. (CVSI) Q3 2025 Earnings Call Prepared Remarks Transcript
CV Sciences, Inc. Reports Third Quarter 2025 Financial Results
CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025
CV Sciences Launches Ignite: A Men's Performance Formula for Vitality, Recovery, Libido & Focus
CV Sciences, Inc. (CVSI) Q2 2025 Earnings Call Transcript
CV Sciences, Inc. Reports Second Quarter 2025 Financial Results
CV Sciences, Inc. To Announce Second Quarter 2025 Results On August 13, 2025
CV Sciences, Inc. Applauds Governor Abbot's Veto of Senate Bill 3
CV Sciences, Inc. (CVSI) Q1 2025 Earnings Call Transcript
CV Sciences, Inc. Reports First Quarter 2025 Financial Results